FI905956A0 - Foerfarande foer producering av ett biologiskt aktivt protein. - Google Patents

Foerfarande foer producering av ett biologiskt aktivt protein.

Info

Publication number
FI905956A0
FI905956A0 FI905956A FI905956A FI905956A0 FI 905956 A0 FI905956 A0 FI 905956A0 FI 905956 A FI905956 A FI 905956A FI 905956 A FI905956 A FI 905956A FI 905956 A0 FI905956 A0 FI 905956A0
Authority
FI
Finland
Prior art keywords
aktivt
biologiskt
ett
protein
foerfarande foer
Prior art date
Application number
FI905956A
Other languages
English (en)
Other versions
FI103278B1 (fi
FI103278B (fi
FI905956A (fi
Inventor
Nico Cerletti
Gary Kent Mcmaster
David Cox
Albert Schmitz
Bernd Meyhack
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI905956A0 publication Critical patent/FI905956A0/fi
Publication of FI905956A publication Critical patent/FI905956A/fi
Application granted granted Critical
Publication of FI103278B1 publication Critical patent/FI103278B1/fi
Publication of FI103278B publication Critical patent/FI103278B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1841Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI905956A 1989-12-06 1990-12-03 Menetelmä biologisesti aktiivisen TGF- :n kaltaisen proteiinin tuotta miseksi FI103278B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8927546 1989-12-06
GB898927546A GB8927546D0 (en) 1989-12-06 1989-12-06 Process for the production of biologically active tgf-beta

Publications (4)

Publication Number Publication Date
FI905956A0 true FI905956A0 (fi) 1990-12-03
FI905956A FI905956A (fi) 1991-06-07
FI103278B1 FI103278B1 (fi) 1999-05-31
FI103278B FI103278B (fi) 1999-05-31

Family

ID=10667491

Family Applications (1)

Application Number Title Priority Date Filing Date
FI905956A FI103278B (fi) 1989-12-06 1990-12-03 Menetelmä biologisesti aktiivisen TGF- :n kaltaisen proteiinin tuotta miseksi

Country Status (23)

Country Link
US (2) US5650494A (fi)
EP (2) EP0433225B1 (fi)
JP (1) JP3048061B2 (fi)
KR (1) KR100203230B1 (fi)
AT (1) ATE178616T1 (fi)
AU (1) AU638075B2 (fi)
CA (1) CA2031430C (fi)
DE (1) DE69033040T2 (fi)
DK (1) DK0433225T3 (fi)
ES (1) ES2132066T3 (fi)
FI (1) FI103278B (fi)
GB (1) GB8927546D0 (fi)
GR (1) GR3030703T3 (fi)
HU (1) HU218144B (fi)
IE (2) IE990992A1 (fi)
IL (1) IL96549A (fi)
MX (1) MX172600B (fi)
NO (1) NO301768B1 (fi)
NZ (1) NZ236333A (fi)
PH (1) PH31649A (fi)
PT (1) PT96068B (fi)
SG (1) SG52690A1 (fi)
ZA (1) ZA909762B (fi)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
DE69129747T2 (de) * 1990-09-05 1998-11-12 Southern Cross Biotech Pty. Ltd., Toorak, Victoria In lösung bringen von proteinen in aktiver form
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
DE69233022T2 (de) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US20080139474A1 (en) * 1991-11-04 2008-06-12 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US6884787B2 (en) * 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
DE4243729A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Reaktivierung von gereinigten Membranproteinen
AU5955294A (en) * 1993-01-08 1994-08-15 Upjohn Company, The Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
DE69432375T2 (de) 1993-04-30 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
EP0670733A1 (en) * 1993-09-29 1995-09-13 Alcon Laboratories, Inc. Compositions containing growth factors and antiplastic agents
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
EP0733109B9 (en) * 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
AU3109795A (en) * 1994-07-25 1996-02-22 Novartis Ag Process for folding of proteins like recombinant hirudin or epidermal growth factor
TW440566B (en) * 1994-07-25 2001-06-16 Novartis Ag Novel process for the production of biologically active dimeric protein
BR9608019A (pt) * 1995-04-19 1999-11-30 Hoechst Japan Uma nova proteína e um processo para a preparação da mesma'
US5714371A (en) * 1995-05-12 1998-02-03 Schering Corporation Method for refolding insoluble aggregates of hepatitis C virus protease
US6352972B1 (en) * 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
CA2235223A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
DE69636739T2 (de) * 1995-12-21 2007-10-18 Ajinomoto Co., Inc. Verfahren zur rückfaltung von menschlichem activin a
EP0876401B1 (en) * 1996-01-22 2007-06-13 Curis, Inc. Methods for producing op-1 morphogen analogs
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US7811793B2 (en) 1996-12-25 2010-10-12 Biopharma Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Process for preparing purified active monomer of bone-derived factor
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
US6500920B1 (en) * 1997-06-19 2002-12-31 St. Louis University Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
DE69714035T2 (de) 1997-08-14 2003-03-06 Sulzer Innotec Ag, Winterthur Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
DE19749259A1 (de) * 1997-11-07 1999-05-12 Dade Behring Marburg Gmbh Verfahren zur Herstellung von funktionalem rekombinantem Gewebsfaktor
PT1584685E (pt) * 1998-02-05 2011-06-17 Glaxosmithkline Biolog Sa Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
JP3762222B2 (ja) * 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型TGF−βスーパーファミリータンパク質
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
WO2000040610A1 (fr) * 1999-01-07 2000-07-13 Takeda Chemical Industries, Ltd. Procede de production de proteines activees
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
DE19906096A1 (de) 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
CA2370539C (en) 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
DE19944626A1 (de) * 1999-09-17 2001-03-22 Knoell Hans Forschung Ev Verfahren zur Herstellung von dimeren, biologisch aktiven knochenmorphogenetischen Proteinen
CA2402160C (en) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
DE10026713A1 (de) * 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
US7081240B1 (en) * 2000-06-28 2006-07-25 Zimmer Orthobiologics, Inc. Protein mixtures for wound healing
JP4911865B2 (ja) 2000-09-12 2012-04-04 マサチューセッツ インスティテュート オブ テクノロジー 低分子量ヘパリンに関連する方法および生成物
JP2004523479A (ja) 2000-10-18 2004-08-05 マサチューセッツ インスティテュート オブ テクノロジー 多糖の肺送達に関する方法および産物
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
CZ20032208A3 (cs) 2001-02-23 2004-01-14 Immunex Corporation Zvýšený výtěžek aktivních proteinů
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
ATE393573T1 (de) * 2001-06-01 2008-05-15 Wyeth Corp Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
NZ532021A (en) 2001-10-04 2008-05-30 Genetics Inst Llc Methods and compositions for modulating interleukin-21 receptor activity
US7232802B2 (en) 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
SI1472286T1 (sl) * 2002-02-05 2007-08-31 Geymonat Spa Postopek proizvodnje rekombinantnega placentnega rastnega faktorja
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
CN1735426A (zh) 2002-08-13 2006-02-15 惠氏公司 用作转化生长因子β蛋白质的溶解赋形剂的肽
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 潤滑油組成物
US7074412B2 (en) 2003-01-30 2006-07-11 The University Of Zurich Pharmaceutical composition
ES2479942T3 (es) 2003-04-18 2014-07-25 Biogen Idec Ma Inc. Neublastina glucosilada conjugada con polímero
PT1675608E (pt) 2003-09-12 2007-05-31 Etex Corp Barras sólidas e pastas de fosfato de cálcio injectável para a libertação de proteínas osteogénicas.
EP2338441B1 (en) 2003-12-11 2013-01-23 Isto Technologies Inc. Particulate cartilage system
RS51453B (en) * 2004-08-19 2011-04-30 Biogen Idec Ma Inc. NEUBLASTIN
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
US20060166251A1 (en) * 2005-01-26 2006-07-27 Archambault Joanne M Use of sFRPs as markers of BMP activity
AU2006214473A1 (en) 2005-02-14 2006-08-24 Wyeth Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
AU2006214384A1 (en) 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation
WO2006105359A2 (en) * 2005-03-30 2006-10-05 Wyeth Methods for stimulating hair growth by administering bmps
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
CN101511858A (zh) * 2005-07-25 2009-08-19 特鲁比昂药品公司 用于蛋白质解聚的组合物和方法
GB0516204D0 (en) * 2005-08-06 2005-09-14 Riotech Pharmaceuticals Ltd Methods
WO2007025290A2 (en) 2005-08-26 2007-03-01 Isto Technologies, Inc. Implants and methods for repair, replacement and treatment of joint disease
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
GB0604938D0 (en) 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604964D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
AU2007272412B2 (en) * 2006-07-14 2013-11-07 Genentech, Inc. Refolding of recombinant proteins
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
CA2668771C (en) 2006-11-08 2016-03-15 Wyeth Rationally designed media for cell culture
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
AU2008240191B2 (en) 2007-04-12 2013-09-19 Zimmer, Inc. Compositions and methods for tissue repair
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
US20090042253A1 (en) 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
EP2192904B1 (en) 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
EP2341913B1 (en) 2008-09-16 2014-11-19 Saint Louis University Method of enhancing tgf-beta signalling
US8494140B2 (en) * 2008-10-30 2013-07-23 Centurylink Intellectual Property Llc System and method for voice activated provisioning of telecommunication services
WO2010051360A1 (en) 2008-10-31 2010-05-06 Wyeth Llc Purification of acidic proteins using ceramic hydroxyapatite chromatography
WO2011005488A1 (en) * 2009-06-22 2011-01-13 Amgen Inc. Refolding proteins using a chemically controlled redox state
JP2012531428A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
KR100991203B1 (ko) 2010-05-10 2010-11-01 심영복 골형성 단백질의 정제 방법
WO2012029148A1 (ja) 2010-09-01 2012-03-08 株式会社オステオファーマ 組換えヒト骨形成タンパク質-2凍結乾燥製剤
TWI649095B (zh) * 2012-02-10 2019-02-01 捷百克股份有限公司 以非人類幹細胞之培養上清液為起始材料之化妝品或皮膚再生促進劑、及蛋白質之離子導入法
US10188732B2 (en) 2012-08-06 2019-01-29 Biogen Ma Inc. Methods and compositions for inactivating enveloped viruses
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
EP3562839A4 (en) 2016-12-30 2020-09-02 Biogend Therapeutics Co., Ltd. RECOMBINANT POLYPEPTIDES, ASSOCIATED COMPOSITIONS AND PROCESSES

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1155109A (en) * 1980-03-27 1983-10-11 Ronald E. Chance Process for producing an insulin
GR79124B (fi) * 1982-12-22 1984-10-02 Genentech Inc
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
WO1984004924A1 (en) * 1983-06-03 1984-12-20 Us Commerce Purified transforming growth factor-beta derived from human platelets and placentas
DE3587022T2 (de) * 1984-02-17 1993-06-17 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4731440A (en) * 1985-02-22 1988-03-15 Monsanto Company Method of somatotropin solubilization using dimethylsulfone and naturation
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
GB8508340D0 (en) * 1985-03-29 1985-05-09 Creighton T E Production of protein
EP0208539A3 (en) * 1985-07-11 1988-08-03 Repligen Corporation Folding disulfide-cross-linkable proteins
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
NZ222569A (en) * 1986-11-17 1990-08-28 Sandoz Ltd Production of glioblastoma-derived t cell suppressor factor (g-tsf) using recombinant techniques
FI100106B (fi) * 1986-12-05 1997-09-30 Novartis Ag Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US5162507A (en) * 1987-05-11 1992-11-10 Cetus Corporation Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms
ATE156491T1 (de) * 1987-05-11 1997-08-15 Chiron Corp Prozess zur gewinnung von gereinigtem, oxidiertem, renaturiertem, rekombinantem interleukin-2 aus mikroorganismen
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US4985544A (en) * 1987-08-04 1991-01-15 Kyowa Hakko Kogyo Co., Ltd. Process for renaturing fish growth hormone
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5144006A (en) * 1991-06-13 1992-09-01 The Rockefeller University Oxidative folding of peptide and protein substrates using hydrocarbon sulfoxides
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors

Also Published As

Publication number Publication date
AU6701890A (en) 1991-06-13
FI103278B1 (fi) 1999-05-31
IL96549A0 (en) 1991-09-16
FI103278B (fi) 1999-05-31
IE990992A1 (en) 2000-12-13
US5650494A (en) 1997-07-22
JP3048061B2 (ja) 2000-06-05
DE69033040D1 (de) 1999-05-12
NO905264D0 (no) 1990-12-05
EP0891985A1 (en) 1999-01-20
KR100203230B1 (ko) 1999-06-15
HUT56880A (en) 1991-10-28
IL96549A (en) 2000-10-31
IE904386A1 (en) 1991-06-19
MX172600B (es) 1994-01-03
ES2132066T3 (es) 1999-08-16
EP0433225B1 (en) 1999-04-07
HU908084D0 (en) 1991-06-28
PT96068B (pt) 1998-02-27
GB8927546D0 (en) 1990-02-07
AU638075B2 (en) 1993-06-17
HU218144B (hu) 2000-06-28
GR3030703T3 (en) 1999-11-30
ATE178616T1 (de) 1999-04-15
NO301768B1 (no) 1997-12-08
JPH03191791A (ja) 1991-08-21
NZ236333A (en) 1992-03-26
PH31649A (en) 1999-01-12
US5922846A (en) 1999-07-13
CA2031430A1 (en) 1991-06-07
DK0433225T3 (da) 1999-10-25
ZA909762B (en) 1991-08-28
NO905264L (no) 1991-06-07
EP0433225A1 (en) 1991-06-19
DE69033040T2 (de) 1999-09-09
SG52690A1 (en) 1998-09-28
KR910012240A (ko) 1991-08-07
FI905956A (fi) 1991-06-07
CA2031430C (en) 2003-05-27
PT96068A (pt) 1991-09-30

Similar Documents

Publication Publication Date Title
FI905956A0 (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
ATE92929T1 (de) Komplexe verbindungen aus bioflavonoiden mit phospholipiden, ihre herstellung und verwendung und sie enthaltende pharmazeutische und kosmetische zusammensetzungen.
ATE114169T1 (de) Morphogenetisches knochenprotein.
FR2680507B1 (fr) Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE71375T1 (de) Substituierte 6-fluor-4-oxo-1,4-dihydrochinolin-3-carbonsaeure ; deren derivate; diese verbindung enthaltende pharmazeutische zubereitungen und verfahren zur herstellung dieser verbindungen.
FI890311A0 (fi) Kemiska foereningar.
SE8404065D0 (sv) Novel biologically active compounds
DK0406745T3 (da) Antibiotiske GE 2270 faktorer A1, A2, A3 og H
JPS56138174A (en) Phenylpiperazine derivative of 1,3,4-oxadiazolylphenol, manufacture and medicine containing same
EP0318029A3 (en) Cyclic amine and pharmacological composition
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
ATE85893T1 (de) Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis.
ATE122563T1 (de) Verwendung von 15-keto-prostansäure-derivaten zur herstellung eines medikaments für die verbesserung der ausscheidung des kaliumions.
SE8802323L (sv) 8alfa-acylaminoergolin, dess framstaellning samt farmaceutiska kompositioner innehaallande detsamma
ATE53384T1 (de) 3-mercapto-2-oxo-1-pyrrolidinessigsaeurederivate verfahren zur herstellung und pharmazeutische zusammensetzungen die sie enthalten.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Owner name: NOVARTIS AG